Physician
Internal Medicine
Dr. Jennifer Wheler, MD
|
|
Give Review
Jennifer Wheler practices Internal Medicine. She went to Weill Cornell Medical College of Cornell University. Weill Cornell Medical College of Cornell University is ranked 18 in research and 49 in primary care medicine Jennifer Wheler is a published doctor. She published 93 publications, including: 'Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.' She accepts all Medicare patients.
Publications
- Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced Cancer.
- Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
- Novel phase I study combining G1 phase, S phase, and G2/M phase Cell cycle inhibitors in patients with advanced malignancies.
- Phase I trial of valproic acid and lenalidomide in patients with advanced Cancer.
- Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung Cancer.
- MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.
- Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
- Olanzapine for cachexia in patients with advanced Cancer: an exploratory study of effects on weight and metabolic cytokines.
- Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung Cancer.
- Androgen receptors beyond prostate Cancer: an old marker as a new target.
- Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit.
- Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities.
- Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid Tumors.
- Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab.
- Targeted PI3K/AKT/mTOR therapy for metastatic Carcinomas of the cervix: A phase I clinical experience.
- Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic.
- A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced Cancer.
- Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I clinic.
- Unique Molecular Landscapes in Cancer: Implications for Individualized, Curated Drug Combinations.
- Triple Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents.
- Outcomes of patients with advanced Cancer and KRAS mutations in phase I clinical trials.
- Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of...
- Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid Tumors.
- Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses.
- Characteristics and survival of patients with advanced Cancer and p53 mutations.
- Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.
- First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid Tumors.
- Anastrozole and everolimus in advanced gynecologic and Breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
- Outcomes of patients with metastatic cervical Cancer in a phase I clinical trials program.
- Unique molecular signatures as a hallmark of patients with metastatic breast Cancer: Implications for current treatment paradigms.
- Evaluation of a novel blood pressure scoring method and its association with clinical response in Cancer patients treated with anti-vascular endothelial growth factor ...
- Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced Cancer.
- MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory Cancers: an open-label, phase 1 dose-escalation and expansion study.
- MET aberrations and c-MET inhibitors in patients with gastric and esophageal Cancers in a phase I unit.
- Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.
- Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced Cancers.
- Phase I clinical trial of bendamustine and bevacizumab for patients with advanced Cancer.
- Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors.
- A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on...
- Barriers to Study Enrollment in Patients With Advanced Cancer Referred to a Phase I Clinical Trials Unit.
- Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA mutations.
- Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial.
- Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced Cancer.
- A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid Tumors.
- Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
- Combining Erlotinib and Cetuximab is Associated with Activity in Patients with Non Small Cell Lung Cancer (including Squamous Cell Carcinomas) and Wild-Type EGFR or Re...
- Body composition and survival in the early clinical trials setting.
- A pilot study of temsirolimus and body composition.
- Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid Carcinoma on long-term RET inhibitor therapy.
- P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy.
- Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid Tumors.
- Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced Tumors: implications for therapy.
- Factors related to biopsy willingness in patients with advanced Cancer in a phase 1 clinic for molecularly targeted therapy.
- Bevacizumab-based treatment in colorectal Cancer with a NRAS Q61K mutation.
- A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced Cancers and predo...
- Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung Cancer.
- PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
- Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the Liver.
- Electrocardiograms (ECGs) in phase I antiCancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs.
- Advance Care Planning in Patients With Cancer Referred to a Phase I Clinical Trials Program: The MD Anderson Cancer Center Experience.
- Change in Tumor Size by RECIST Correlates Linearly With Overall Survival in Phase I Oncology Studies.
- Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies.
- Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies.
- Outcomes in 144 Patients With Colorectal Cancer Treated in a Phase I Clinic: the MD Anderson Cancer Center Experience.
- Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience.
- MET nucleotide variations and amplification in advanced ovarian Cancer: characteristics and outcomes with c-Met inhibitors.
- Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal Cancer.
- Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.
- FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors.
- Retreatment after Secondary Resistance or Mixed Response: A Pilot Study.
- Outcomes of research biopsies in phase I clinical trials: the MD anderson Cancer center experience.
- Outcome analyses after the first admission to an intensive care unit in patients with advanced Cancer referred to a phase I clinical trials program.
- A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced Cancer.
- Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience.
- Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the Breast: biologic rationale and implications for stem-cell research in...
- Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson Cancer center experience.
- Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors.
- Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib ...
- PIK3CA mutations in patients with advanced Cancers treated with PI3K/AKT/mTOR axis inhibitors.
- Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced Cancer and dominant liver involvement.
- Phase 1 clinical trials in 83 patients with pancreatic Cancer: The M. D. Anderson Cancer Center experience.
- A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with Systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tu...
- Phase I clinical trials in 85 patients with gynecologic Cancer: the M. D. Anderson Cancer Center experience.
- PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells.
- Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse.
- Clinical outcomes of patients with breast Cancer in a phase I clinic: the M. D. Anderson Cancer center experience.
- Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.
- Phase I clinical trials in 56 patients with thyroid Cancer: the M. D. Anderson Cancer Center experience.
- A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate Cancer.
- Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience.
- Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast Cancer: a phase I dose-escalatio...
- Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast Cancer: evidence and ongoing controversy.
Schools
Weill Cornell Medical College
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Internal Medicine
Accepted Insurances
Education
-
Yale-New Haven Hospital -
New York Presbyterian Hospital -
Weill Cornell Medical College of Cornell University
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1952313959 | |
| NPPES Provider LastName | WHELER | |
| NPPES Provider FirstName | JENNIFER | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 448.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 38.0 | |
| Percent Opioid Claims | 8.48 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1952313959 |
| Last Name Of The Provider | WHELER |
| First Name Of The Provider | JENNIFER |
| View All |
Similar Doctors
|
|
Dr. Bettina I. Cardus, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicolas A. Villa, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Manoj Thangam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anam Khan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Imad Shureiqi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jacqueline S. Hart, MD |
|
|
Dr. Salim S. Virani, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Zahida Yasin, MD
This Doctor is OpenDoctor Recommended.
|